T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Status:
Completed
Trial end date:
2015-04-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body
irradiation before a donor umbilical cord blood transplant helps stop the patient's immune
system from rejecting the donor's stem cells. The donated stem cells may replace the
patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor
effect). Giving an infusion of the donor's T-regulatory cells after the transplant may
decrease this effect. Sometimes the transplanted cells from a donor can also make an immune
response against the body's normal cells. However, the donor immune system may also react
against the recipient's tissues (graft-versus-host disease).
PURPOSE: This phase I trial is studying the side effects and best dose of donor T-regulatory
cells after an umbilical cord blood transplant in treating patients with advanced hematologic
cancer or other disorder.